Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 16172755 | HLA (HLA) | jorge lobos disease | NA | NA | NA | negation | |
| the result did not show any association between hla antigens and jorge lobo's disease. | |||||||
| 16172755 | HLA-DRB1*07 | jorge lobos disease | NA | NA | NA | unclassified | |
| this suggests a negative association (protective) between hla-dr7 and jorge lobo's disease. | |||||||
| 16210487 | HLA-A*02 | lassa fever | NA | NA | NA | unclassified | |
| lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-t-lymphocyte responses in hla-a2.1 transgenic mice. | |||||||
| 25483693 | HLA-DR3 (BROAD ANTIGEN) | lassa fever | NA | NA | NA | positive | |
| we demonstrated that the lassa fever vaccine induced significantly increased class ii peptide specific interferon-g cd4(+) t cell responses in hla-dr3 transgenic mice compared to peptide or mav alone controls. | |||||||
| 22509813 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | dry eye disease | Chinese | NA | NA | unclassified | |
| association of killer cell immunoglobulin-like receptor and human leukocyte antigen-c genotype with dry eye disease in a chinese han population. | |||||||
| 30374345 | HLA-DRB1 (HLA-DRB1) | dry eye disease | NA | NA | NA | unclassified | |
| conjunctival inflammatory gene expression profiling in dry eye disease: correlations with hla-dra and hla-drb1. | |||||||
| 30374345 | HLA-DR (HLA-DR) | dry eye disease | NA | NA | NA | unclassified | |
| purpose: in several multicenter clinical trials, hla-dr was found to be a potential biomarker of dry eye disease (ded)'s severity and prognosis. | |||||||
| 34585595 | HLA-DR (HLA-DR) | fluorescein | NA | loteprednol | NA | only_studied | |
| NA | |||||||
| 16257267 | HLA-B*44 | autoimmune lymphoproliferative syndrome | NA | NA | NA | negative | |
| hla b44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with cd95 defects (alps type ia). | |||||||
| 16277856 | MHC (MHC) | graft versus host diseases | NA | NA | NA | unclassified | |
| in conclusion, arc ii ta inhibited c ii ta and thus the family of mhc ii molecules were regulated by it, therefore these results provide a novel approach for the control of graft versus host diseases. | |||||||
Copyright 2024